FREQUENCY THERAPEUTICS INC stock forecast: up to 8.83 USD FREQ stock price prognosis
Forecast for Thu 16 Dec 2021 price
FREQUENCY THERAPEUTICS INC stock price forecast for further price development up to 28.89% (time horizon: 1 day) and price target of 8.83 USD. Short-term (time horizon: 2 weeks) FREQUENCY THERAPEUTICS INC share price prediction for 2021-12-16 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
No treatment-related serious adverse events were observed in the study. Hearing function was tested over the course of 90 days following dosing. This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated. Validated measures of hearing including WR, WIN, and pure tone audiometry will be used. We expect to share results from this clinical trial in the second quarter of 2021. Hearing aids also cannot repair the underlying pathology of hearing loss. There are also further direct and indirect impacts on individuals suffering from SNHL. Humans are born with about 15,000 hair cells in the cochlea of each ear. 8226; Difficulties with background noise. FX-322 was observed to be well-tolerated in this trial. A p value is the probability that the difference between two data sets was due to chance. Despite the change, the results were consistent with the figure above. & & Group three received four injections of FX-322. We are pursuing this and other approaches to stimulating myelination of axons in MS. We also have the right to grant sublicenses under the Cambridge License. Upon entering into the Cambridge License, we made a $50.0 thousand license fee payment. We have the right to terminate for any reason upon 90 days' prior written notice. There are three manufacturers of cochlear implants that market in the United States. Some preclinical testing may continue even after the IND is submitted. We are a clinical-stage biotechnology company with a limited operating history. We were established and began operations in 2014. We or Astellas may not be in a position to do so for several years, if ever. As a result, increasingly high barriers are being erected to the entry of new products. In addition, the CCPA went into effect on January 1, 2020. These changes may lead to additional costs and increase our overall risk exposure.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 37.36/100
Good financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
FREQUENCY THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for FREQUENCY THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for FREQUENCY THERAPEUTICS INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for FREQUENCY THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for FREQUENCY THERAPEUTICS INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for FREQUENCY THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for FREQUENCY THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for FREQUENCY THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio